Immunization with combined HSV-2 glycoproteins B2 : D2 gene DNAs: protection against lethal intravaginal challenges in mice.
The immunity of a combined DNA vaccine of HSV-2 glycoproteins B2 (gB2) and D2 (gD2) genes in comparison to individual vaccines was studied with regard to protecting against the HSV infection. Two recombinant DNA vaccines of the pHS2-gB2 or pHS2-gD2 were constructed and formulated. The neutralizing antibody titers appeared higher in the B2 : D2 gene cocktail-vaccinated mice than that of the individual B2 or D2 gene-vaccinated group alone, and the positive KOS control induced higher titer of the neutralizing antibody than combined or individual gene vaccines. The mock-immunized mice failed to induce enough. The ranks for the CTL activity and the protection rates against the lethal intravaginal challenge were shown as KOS > B2:D2 cocktail > D2 > B2 gene vaccines. The vaginal external diseases in the B2 : D2 or D-vaccinated mice were significantly reduced against the challenging dosages. The virus titers in the vaginal secretions of the vaccinated mice significantly reduced with time, and the B2 : D2 gene vaccine decreased more than each individual vaccine alone. It can be concluded that the cocktailed vaccines are more effective in the humoral and cellular immune responses in the mice, and in the protection of the mice against the intravaginal challenging dosages when compared with individual gene vaccines. All the DNA vaccines failed to block the latent infection in sensory nerves.
Lee
Hyung Hoan
HH
Department of Biological Sciences, Konkuk University, Seoul, Republic of Korea. hhlee@konkuk.ac.kr
Cha
Soung Chul
SC
Jang
Dong June
DJ
Lee
Jun Keun
JK
Choo
Dong Wan
DW
Kim
Young Sik
YS
Uh
Hong Sun
HS
Kim
Soo Young
SY
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006558:Herpes Genitalis / Q000517:prevention & control* / Q000821:virology; D018258:Herpesvirus 2, Human / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D022283:Herpesvirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D051379:Mice; D009500:Neutralization Tests; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*; D014621:Vagina / Q000821:virology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D017735:Virus Latency
D000914:Antibodies, Viral; D022283:Herpesvirus Vaccines; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; C044525:glycoprotein B, herpes simplex virus type 2; C040570:glycoprotein D-herpes simplex virus type 2